Prot #GS29250: A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients with Persistent Moderate to Severe Atopic Dermatitis that is Inadequately Controlled by Topical Corticosteroids

  • Silverberg, Jonathan I (PD/PI)

Project: Research project

Project Details

Effective start/end date5/8/155/8/18


  • INC Research, LLC (Prot #GS29250 // Prot #GS29250)
  • Genentech, Inc (Prot #GS29250 // Prot #GS29250)